Letter to the editorMethotrexate (MTX) is a folic acid antagonist that prevents cell replication by disrupting DNA, RNA, thymidylate, and protein synthesis through the inhibition of dihydrofolate reductase. Its capacity to cross the blood-brain barrier and eliminate leukemic cells from the central nervous system makes MTX a critical component in the treatment of acute lymphoblastic leukemia (ALL) [1-3]. However, MTX can also cause adverse effects such as neurotoxicity, myelosuppression, mucositis, liver damage, and kidney failure [2,3]. Patients with leukemia may exhibit focal neurological deficits due to various conditions, including cerebral infarction, intracranial hemorrhage, and infection. MTX-induced neurotoxicity can present with stroke-like symptoms, which may be difficult to distinguish from those of an actual stroke [4,5]. We report a case of MTX-induced stroke-like leukoencephalopathy in a patient with ALL who experienced complete neurological recovery. This study received approval from the Institutional Review Board of Daegu Catholic University Medical Center (CR-24-005). The requirement for obtaining publication consent was waived, as this report contains no personally identifiable protected health information.An 18-year-old man with ALL was admitted for delayed intensification chemotherapy. Five days after receiving intrathecal (IT) triple therapy (MTX 15 mg, cytarabine 30 mg, and hydrocortisone 15 mg), he developed weakness in his right arm. Within the next 18 hours, his motor weak-1 www.annchildneurol.org